Literature DB >> 15081328

Effects of hypertonic dextran in hypovolaemic shock: a prospective clinical trial.

Emin Kaya Alpar1, Vijay Vardhan Killampalli.   

Abstract

The aim of this paper is to report the results of prospective clinical trials of hypertonic saline dextran (HSD) in the resuscitation of hypovolaemic shock in critically injured patients. There are many types of fluids, which can be administered intravenously. Recent interest in the usage of HSD solution has confirmed that they have a place in resuscitation of a patient in shock. Heart rate and arterial pressure recovered well with HSD solution. The plasma osmolarity, sodium and potassium levels were significantly elevated in patients resuscitated with HSD. Urine output recovered rapidly and was well maintained throughout.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081328     DOI: 10.1016/S0020-1383(03)00196-7

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  4 in total

1.  Hypertonic saline dextran after burn injury decreases inflammatory cytokine responses to subsequent pneumonia-related sepsis.

Authors:  Jureta W Horton; David L Maass; D Jean White
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-11-18       Impact factor: 4.733

Review 2.  Choice of fluids for resuscitation in children with severe infection and shock: systematic review.

Authors:  Samuel Akech; Hannah Ledermann; Kathryn Maitland
Journal:  BMJ       Date:  2010-09-02

3.  Colloids versus crystalloids for fluid resuscitation in critically ill people.

Authors:  Sharon R Lewis; Michael W Pritchard; David Jw Evans; Andrew R Butler; Phil Alderson; Andrew F Smith; Ian Roberts
Journal:  Cochrane Database Syst Rev       Date:  2018-08-03

4.  Fluid resuscitation in critically ill patients: a systematic review and network meta-analysis.

Authors:  Chao Liu; Zhi Mao; Pan Hu; Xin Hu; Hongjun Kang; Jie Hu; Zhifang Yang; Penglin Ma; Feihu Zhou
Journal:  Ther Clin Risk Manag       Date:  2018-09-12       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.